EXCELYA
6.7.2020 08:02:10 CEST | Business Wire | Press release
Today, Excelya, a leading contract research organization (CRO) specializing in clinical research, announced that three European CROs joined Excelya Group: Zeincro based in Central-Eastern & Southern Europe, The Clinical Company based in the Netherlands and Belgium and Koehler eClinical based in Germany. Together, they will be known as Excelya Group. This alliance will allow Excelya to offer a one stop provider service model throughout Europe for its clients, whether they need full service, functional service providing or consulting services.
Zeincro is a leading contract research organization primarily operating in Central-Eastern & Southern Europe with particular expertise in clinical operations, safety and medical affairs. The Clinical Company is present in the Belgian and Dutch markets specializing in clinical operations. Koehler eClinical is a German specialty CRO with a focus on biostatistics and data solutions. Thanks to the unification with these three companies, Excelya Group is now a leading European full service CRO providing services in 24 European countries. Excelya Group now employs 800 people in six areas of expertise, with expected combined revenues of €70 million in 2020.
Francois Moisson, CEO at Excelya: “Our newly European scale and reach will allow us to provide a full suite of end-to-end clinical solutions for our clients where they need them. These investments in innovation and delivery capacity position us to rapidly continue our growth in the short and medium term.”
About Excelya Group
Excelya is an independent European contract research organization with over 800 employees, 17 offices and 12 legal entities spread throughout Europe. Excelya offers all cooperation models, from consulting to functional service providing to full-service. It provides these research services across multiple industries, including pharmaceutical, biotech, medical devices, cosmetics and nutrition. As a fully integrated CRO, Excelya undertakes the design and execution of Phase I clinical trials to post-marketing studies, safety, biometrics and market access projects. Excelya is committed to providing preeminent experts who work hand-in-hand with its clients to accelerate end-to-end drug development, leverage data science and reimagine patient care.
For more information, please visit excelya.com .
About Zeincro
Zeincro is a CRO created in 1999 headquartered in the United Kingdom that provides services to more than 20 countries in Central-Eastern & Southern Europe through eight offices. Zeincro provides a full range of services from Phases I to IV with a specialization in clinical operations and safety across most therapeutic areas. With almost 20 years of experience in more than 700 successful clinical studies completed, Zeincro has developed a thorough understanding of the communities and the regions in which it operates. This approach allows ZEINCRO to set new standards for successful clinical trials by delivering bespoke services that maximize patient recruitment and compliance.
For more information, please visit zeincro.com .
About Koehler eClinical GmbH
Koehler eClinical GmbH is a mid-size specialty CRO with more than 25 years of experience in providing value-added services for its customers. With its strong heritage in biostatistics, it covers all study phases as well as biostatistical and regulatory consulting, meta-analyses, data integration and standardizations. As a specialist in data-centric approaches, the company also operates its proprietary software VITESSA as a combined tool for electronic data capture and clinical trial management. Koehler eClinical GmbH provides full-service support for local and global trials with centralized project management and technology-enabled approaches. It covers the full spectrum of clinical projects, from early to late-phase, including NIS, observational and PASS.
For more information, please visit koehler-eclinical.com .
About The Clinical Company
Founded in 2002, The Clinical Company is based in Amstelveen, The Netherlands and Leuven, near Brussels, Belgium. The Clinical Company specializes in delivering clinical services in the Benelux to their (Bio)Pharmaceutical, Medical Device and CRO Clients. The Clinical Company is a full service CRO that provides services from Phases I to IV in all major therapeutic areas and conducts clinical trials in eight countries in Western Europe.
For more information, please visit theclinicalcompany.com .
Project Contributors :
- Excelya: François Moisson & Frédéric Paqueville (CEO & Co-Founders), Guillaume Steimer
-
Legal counsel:
- FieldFisher: Philippe Netto, Hélène Lefebvre, Antoine Gabizon (Fr), Mark Walker (UK), Louis Bouchez and Jan Schouten (NL), Florian Streiber (D), Louis-Francois du Castillon (Bel) ;
- De Pardieu Brocas Maffei: Philippe Rozec
- Financial Audit: Oderis, Aurélien Vion
- Financing: Banking pool (SG,LCL, CIC, HSBC), leading agent: Société Générale, Erkan Suer,
- Zeincro: Dr Gregory Sivolapenko,
- Koehler eClinical: Dr Manfred Koehler, Dr Antal Hajos, Michael Pfitzenmaier,
- The Clinical Company: Pim Van de Riet, Chris de Jong, Evert Cuppens, Stijn Valkering, Angélique Kleemans
-
Legal and financial advisors:
- Zeincro: CMS Cameron McKenna Nabarro Olswang LLP, John Finnemore
- The Clinical Company: CMS Derks Star Busmann N.V, Pieter van Duijvenvoorde, & Breezeholme Advisory Services, Pim van de Riet
- Koehler eClinical: Dr. Reinhard Hermes, & VALNES Corporate Finance GmbH, Michael Graser
View source version on businesswire.com: https://www.businesswire.com/news/home/20200705005014/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
€243B Tech Spend Ahead, but Only 1 in 4 Firms Achieves Scale: WBAM Research Reveals Structural Paradox24.6.2026 12:28:00 CEST | Press release
Research report by Monitor Deloitte and Objectway investigates how and why as-a-service models are gaining ground, and what separates successful execution from failed implementation.Key takeaways Firms are layering resources onto legacy, widening the gap between investment intensity and operational scalability Technology investment alone is insufficient. The real differentiator lies in how Tech&Ops capabilities are sourced, orchestrated, and delivered As-a-service adoption is set to triple in the next 2–3 years, emerging as a key lever to unlock scale According to research conducted by Monitor Deloitte, a consultancy firm, and Objectway, a growth partner for the financial services industry, wealth, banking and asset management (WBAM) firms are investing at record levels, with Technology & Operations spending reaching €173 billion globally and set to hit €243 billion by 2029. However, yet only around one in four firms has achieved true front-to-back scalability, growing their business w
PUMA Dominates HYROX World Championships From Elite Athlete Performances to Community Initiatives24.6.2026 12:15:00 CEST | Press release
Global sports brand PUMA continued its HYROX dominance at the 2026 HYROX World Championships with a host of standout elite athlete performances and iconic community moments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624897869/en/ Global sports brand PUMA continued its HYROX dominance at the 2026 HYROX World Championships with a host of standout elite athlete performances and iconic community moments, including Jake Williamson (left) and Hunter McIntyre in the Men’s Elite15 Doubles. Leading the charge was Jess Pettrow, who won the Mixed Relay with Australia for the second year in a row, with the team defending their title with an epic time of 50:19. Pettrow’s golden moment followed a fourth place finish with partner Joanna Wietrzyk in the Women’s Elite 15 Doubles, making it a highly successful weekend for the PUMA athlete. In addition to her strong showing in the Women’s Elite Doubles, Australian athlete Wietrzyk also
Rockstar Games Announces Pre-Orders for Grand Theft Auto VI24.6.2026 12:15:00 CEST | Press release
Starting at Midnight Local Time on June 25, 2026 Rockstar Games®, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), is excited to announce that pre-orders for Grand Theft Auto VI will begin on June 25, 2026, at midnight local time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624539426/en/ Rockstar Games®, a publishing label of Take-Two Interactive Software, Inc. (NASDAQ: TTWO), is excited to announce that pre-orders for Grand Theft Auto VI will begin on June 25, 2026, at midnight local time. Launching November 19, 2026, for the PlayStation® 5 computer entertainment systems and Xbox Series X|S games and entertainment systems for $79.99, Grand Theft Auto VI features a single-player experience set in the biggest, most immersive evolution of the series yet. Launching November 19, 2026, for the PlayStation® 5 computer entertainment systems and Xbox Series X|S games and entertainment systems for $79.9
Advanced Sterilization Products (ASP) Acquires a Majority Stake in UV Smart24.6.2026 12:00:00 CEST | Press release
Advanced Sterilization Products (ASP), part of the Infection Prevention group of companies within Fortive (NYSE: FTV), announced today it has acquired a majority share of UV Smart, a leader in High Level Disinfection technology in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624367451/en/ UV Smart is renowned for its UV-C High Level Disinfection (HLD) technology that enables faster, safer and lower-cost HLD for specialty scopes. “UV Smart’s dedicated customer relationships and highly skilled team are key strengths that align perfectly with ASP’s long-term growth strategy of infection prevention,” shared Daan Hoek, co-founder of UV Smart. He continued, “Where current cleaning & disinfection processes of TEE probes can often take hours, UV Smart’s premier product, the D60, achieves high-level disinfection using UV-C light in just minutes. For healthcare providers, the D60 represents a significant improvement in ef
Quectel Introduces NXP-based FCM365X Wi-Fi 6, Bluetooth LE 5.4, Zigbee and Thread Module for Smart Home and Industrial IoT Solutions24.6.2026 10:00:00 CEST | Press release
Quectel Wireless Solutions, a global end-to-end IoT solutions provider, today announces the launch of the FCM365X, a dual band Wi-Fi 6 and Bluetooth Low Energy (BLE) 5.4 module that is based on the NXP® Semiconductors RW612 wireless MCU and supports multiple protocols, including Zigbee and Thread. The module is powered by a high-performance Arm® Cortex®-M33 processor with TrustZone® technology, operating at up to 260MHz. It integrates 1.2MB of SRAM and 8MB of Flash memory, with optional PSRAM expansion available, delivering the performance and memory capacity required for demanding IoT applications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260624781458/en/ Quectel introduces NXP-based FCM365X Wi-Fi 6, Bluetooth LE 5.4, Zigbee and Thread module for smart home and industrial IoT solutions As smart home and industrial IoT ecosystems continue to evolve, support for interoperable standards such as Thread and Zigbee is becom
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
